Phase II, Open-Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of Olaparib, a Poly (ADP-Ribose) Polymerase Inhibitor, and Pegylated Liposomal Doxorubicin in Patients With BRCA1 or BRCA2 Mutations and Recurrent Ovarian Cancer

Thumbnail Image
Files
gourley-et-al-2011-phase-ii-open-label-randomized-multicenter-study-comparing-the-efficacy-and-safety-of-olaparib-a.pdf (152.47 KB)
Date
2011-12-27
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Journal of clinical oncology
Abstract
Olaparib (AZD2281), an orally active poly (ADP-ribose) polymerase inhibitor that induces synthetic lethality in BRCA1- or BRCA2-deficient cells, has shown promising clinical efficacy in nonrandomized phase II trials in patients with ovarian cancer with BRCA1 or BRCA2 deficiency. We assessed the comparative efficacy and safety of olaparib and pegylated liposomal doxorubicin (PLD) in this patient population.
Description
Keywords
Citation
Kaye, S. B., Lubinski, J., Matulonis, U., Ang, J. E., Gourley, C., Karlan, B. Y., ... & Kaufman, B. (2012). Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. Journal of clinical oncology, 30(4), 372-379.
URI
https://nru.uncst.go.ug/handle/123456789/9755
Collections
Medical and Health Sciences